Heparin Small Pool High Yield Purified Factor VIII: In Vivo Recovery and Half-Life of Routinely Produced Freeze-Dried Concentrate

Sibinga, C. Th. Smit; Daenen, S; Vanimhoff, Gw; Maas, Anton; Das, P. C.

doi:10.1055/s-0038-1660998

Cited by 14 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have previously reported that the FVIII level is considerably higher in heparinized plasma rather than citrated plasma with average values of 1.3 U/ml in heparin compared to 1.0 U/ml in citrate [2,3]. These results have been substantiated by others [4,5]. We [2] and Morgenthaler et al [4] have also found that heparin, added to citrate plasma or when used as a pri mary anticoagulant, significantly stabilizes FVIII so that a two-phase decay does not occur.…”

supporting

confidence: 56%

Influence of the Primary Anticoagulant on the Recovery of Factor VIII

Rock¹

1988

Vox Sanguinis

View full text Add to dashboard Cite

supporting

confidence: 56%

Influence of the Primary Anticoagulant on the Recovery of Factor VIII

Rock¹

1988

Vox Sanguinis

View full text Add to dashboard Cite

“…Chelation of the calcium decreases the activity of FVIII that is not bound to vWF (Mikaelsson, Forsman & Oswaldsson, 1983;Rock et al, 1983;Farrugia et al, 1990). Also, in the presence of citrate, FVIII coagulant activity decreases during storage in a biphasic manner (Mikaelsson, Forsman & Oswaldsson, 1983) while collection of blood in heparin renders FVIII coagulant activity noticeably stable for at least 24 h (Krachmalnicoff & Thomas, 1983;Smit Sibinga et al, 1984;Morgenthaler, Zuber & Friedli, 1985;Cumming, Wensley & Delamore, 1986). Shanbrom and Owens (2001) have described the addition of a high concentration of sodium citrate to produce Ôsuper-cryoprecipitateÕ with a yield of both factor VIII and fibrinogen of 97%.…”

Section: Discussionmentioning

confidence: 99%

Cryoprecipitate production: the use of additives to enhance the yield

Yousef

Neurath

Freedman

et al. 2006

Clinical &Amp; Laboratory Haematology

View full text Add to dashboard Cite

Cryoprecipitate is still widely used to treat hemophilia A in developing countries. However, the yield of factor VIII is relatively low averaging, i.e. only 50%. We have attempted to enhance the yield by adding sodium citrate to the plasma following the method of Shanbrom and Owens (Blood 98, 2001, 60a). Fresh-frozen plasma (FFP) units were processed either as control plasma or after the addition of 10% sodium citrate. Cryoprecipitate was produced from both. After resuspension, calcium chloride was added to the citrated cryoprecipitate to correct for excess citrate prior to testing. The levels of FVIII and fibrinogen were determined in both preparations. The citrated cryoprecipitates had varying yields of fibrinogen and FVIII in the cryoprecipitate. The FVIII levels varied from 34% to 215% recovery. Fibrinogen ranged from 55.5% to 121.4%. We found that the addition of increasing amounts of CaCl2 to normal plasma raised the FVIII values from 1.0 to 4 U/ml. To determine the possibility of assay influence we added different quantities of CaCl2 to control plasma and measured the FVIII and activated partial thromboplastin time levels. Addition of citrate to plasma resulted in an increased total amount of cryoprecipitate much of which was citrate. Assays showed considerable ranges in the quantity of FVIII and fibrinogen. Activation of FVIII can be caused by addition of excess calcium.

show abstract

“…well as the good recovery, safety and normal half-disap pearance time of factor VIII derived from heparinized plasma [4,6,9]. Further, we have recently developed a factor VIII/von Willebrand factor concentrate that can be heat treated at 80°C for 72 h to inactivate potential viral contaminants [10].…”

Section: Introductionmentioning

confidence: 99%

“…Further, we have recently developed a factor VIII/von Willebrand factor concentrate that can be heat treated at 80°C for 72 h to inactivate potential viral contaminants [10]. The fractionation results obtained by our group were from heparinized plasma initially frozen and stored at -80°C for a period not in excess of 3 weeks [1,4] prior to routine cryoprecipitation at 4°C or were obtained by others [5,6,9] from plasma snap frozen at -70 °C in an alcohol-dry ice bath and then thawed at 4°C in a water bath for 75-90 min.…”

Section: Introductionmentioning

confidence: 99%

Characterization of Factors Affecting the Stability of Frozen Heparinized Plasma

Palmer¹,

Rosborough²,

Perkins³

et al. 1993

Vox Sanguinis

View full text Add to dashboard Cite

The use of heparin rather than citrate as primary anticoagulant has been shown to significantly improve the initial activity, stability and recovery of factor VIII:C from human plasma, cryoprecipitates or factor VIII concentrates if the plasma was initially frozen at -80°C and subsequently stored at this temperature. If frozen and stored at progressively warmer temperatures however, increasing amounts of insoluble protein aggregates, termed storage precipitates (SPs), were recovered in the thawed plasma and cryoprecipitate fractions. Plasma recovery by centrifugation at 7,000 g for 7 min [Method I (MI)], 2 x 10 min (MII) or 15 min (MIII) had little effect on SP formation after 1 month at any storage temperature. After 4 months at -20°C, more SP was recovered from MI plasma whereas at -40°C, more SP was recovered from MI plasma. Also, the preparation method had little or no effect on factor VIII:C activity at equivalent storage times or temperatures. A trend towards improved factor VIII recoveries was noted at lower freezing and storage temperatures however. SP formation was associated with reduced fibrinogen levels in the recovered plasma without loss of antithrombin-III or increased fibrinopeptide-A. Western blots showed polymerization of Aa or y-chains of fibrinogen. SP formation was reduced or eliminated with factor XIII inhibitors , antibody to the active factor XIII a subunit or adjustment of heparinized plasma to 5-10 mM sodium citrate before initial freezing and storage. Although plasma factor VIII:C recoveries were only slightly affected at these citrate concentrations under most conditions, its recovery in cryoprecipitates was substantially improved owing to the reduction or absence of SPs.

show abstract

Heparin Small Pool High Yield Purified Factor VIII: In Vivo Recovery and Half-Life of Routinely Produced Freeze-Dried Concentrate

Cited by 14 publications

References 7 publications

Influence of the Primary Anticoagulant on the Recovery of Factor VIII

Influence of the Primary Anticoagulant on the Recovery of Factor VIII

Cryoprecipitate production: the use of additives to enhance the yield

Characterization of Factors Affecting the Stability of Frozen Heparinized Plasma

Contact Info

Product

Resources

About